These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 27089321)

  • 1. Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic.
    Flores-Figueroa E; Gratzinger D
    Int J Mol Sci; 2016 Apr; 17(4):553. PubMed ID: 27089321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
    Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
    Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
    Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
    Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow niches in myeloid neoplasms.
    Kitagawa M; Kurata M; Onishi I; Yamamoto K
    Pathol Int; 2020 Feb; 70(2):63-71. PubMed ID: 31709722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated.
    Aanei CM; Catafal LC
    Cytometry A; 2018 Jul; 93(9):916-928. PubMed ID: 30211968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzene exposure--an experimental machinery for induction of myelodysplastic syndrome: stem cell and stem cell niche analysis in the bone marrow.
    Das M; Chaudhuri S; Law S
    J Stem Cells; 2012; 7(1):43-59. PubMed ID: 23550343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
    Miller LH; Qu CK; Pauly M
    Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A replicable CD271+ mesenchymal stromal cell density score: bringing the dysfunctional myelodysplastic syndrome niche to the diagnostic laboratory.
    Gars E; Yousry SM; Babu D; Kurzer JH; George TI; Gratzinger D
    Leuk Lymphoma; 2017 Jul; 58(7):1730-1732. PubMed ID: 27808583
    [No Abstract]   [Full Text] [Related]  

  • 11. Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes.
    Kitagawa M; Kamiyama R; Kasuga T
    Eur J Haematol; 1993 Jul; 51(1):56-8. PubMed ID: 8348949
    [No Abstract]   [Full Text] [Related]  

  • 12. Hematopathological alterations of major tumor suppressor cascade, vital cell cycle inhibitors and hematopoietic niche components in experimental myelodysplasia.
    Chatterjee R; Gupta S; Law S
    Chem Biol Interact; 2017 Aug; 273():1-10. PubMed ID: 28549617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.
    Fattizzo B; Giannotta JA; Barcellini W
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the role of the microenvironment in MDS?
    Calvi LM; Li AJ; Becker MW
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
    Pleyer L; Valent P; Greil R
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
    Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
    Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
    Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
    Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary dysmyelopoiesis in patients with myelodysplastic syndromes].
    Dvirnyk VN; Kokhno AV; Parovichnikova EN
    Ter Arkh; 2014; 86(7):97-103. PubMed ID: 25314785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation by retinoic acid of the growth of bone marrow cell progenitors from patients with myelodysplastic syndrome.
    De Francesco A; Sanavio F; Stacchini A; Piacibello W; Quaglino D; Aglietta M
    Haematologica; 1989; 74(1):25-8. PubMed ID: 2498179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myelodysplastic syndromes--diagnostic and therapeutic problems].
    Skotnicki AB; Piatkowska-Jakubas B; Rucińska M; Zduńczyk A
    Przegl Lek; 1988; 45(11):801-11. PubMed ID: 3072594
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.